ArticleDermatology and therapy2026
Bimekizumab as an Effective Treatment in Darier Disease: Clinical Outcomes of a Single-Center Retrospective Analysis of Patients Treated with Biologics.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDarier disease (DD) is a rare autosomal dominant genodermatosis with limited systemic therapeutic options. Retinoids are the gold standard therapy, but long-term application is frequently limited by adverse events. Case reports suggest that biologicals approved for psoriasis vulgaris or atopic dermatitis may be beneficial in DD.
methodsIn this retrospective study, patients with DD who presented to the Department of Dermatology and Venerology, University Hospital Freiburg, between 2019 and 2024 were identified, and clinical efficacy, patient-reported outcomes, and histological features were analyzed in the patients treated with biologic agents in routine care.
resultsIn total, 15 patients (female: 11, male: 4) with a mean age of 48.20 ± 9.16 years were treated with biologic agents. The three patients who received the type 2 inhibitors dupilumab or lebrikizumab worsened or remained unchanged and discontinued therapy by week 12. Patients treated with the interleukin-17A/F inhibitor bimekizumab showed reduction of the Investigator Global Assessment score and body surface area from a mean of 3.58 ± 0.56 at baseline to 1.80 ± 0.82 at week 24 (p < 0.001) and from 32.00 ± 19.17% to 13.60 ± 9.05% (week 24; p < 0.001), respectively. The Dermatology Life Quality Index score decreased from 18.45 ± 9.87 to 4.78 ± 6.12 (week 24; p < 0.001). Additionally, on histopathology, the total numbers of dyskeratoses showed a trend towards reduction (31.17 ± 10.19 at baseline to 13.67 ± 13.25 at week 12; p = 0.062) with a decrease in the number of grains (10.50 ± 6.77 to 3.33 ± 3.88; p = 0.031).
conclusionsIn summary, these real-world data indicate that bimekizumab may be a beneficial and relatively safe treatment option in DD.
Indexed as
Identifiers
42728531What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.